Search
efgartigimod alfa-fcab (Vyvgart)
Indications:
- treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
- treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in combination with hyaluronidase-qvfc (Vyvgart Hytrulo) [2]
Dosage:
- recommended dosage is 10 mg/kg administered as an intravenous infusion over one hour once weekly for 4 weeks
- in patients weighing >= 120 kg, the recommended dose is 1200 mg per infusion.
- CDIP: weekly 30-to-90 second subcutaneous injection
Injection: 400 mg in 20 mL (20 mg/mL) single-dose vial
Adverse effects:
- hypersensitivity reactions: angioedema, dyspnea, & rash
- common (>= 10%): respiratory tract infections, headache, urinary tract infection
Mechanism of action:
- human IgG1 antibody fragment that binds to & inhibits the neonatal Fc receptor resulting in the reduction of circulating IgG
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
neurologic agent
References
- Wikipedia: Efgartigimod alfa
https://en.wikipedia.org/wiki/Efgartigimod_alfa
- George J
New Treatment Approved for Chronic Inflammatory Demyelinating Polyneuropathy.
Efgartigimod injection reduced CIDP relapse risk
MedPage Today June 23, 2024
https://www.medpagetoday.com/neurology/generalneurology/110782
- HIGHLIGHTS OF PRESCRIBING INFORMATION
VYVGART. (efgartigimod alfa-fcab) injection, for intravenous use